United Therapeutics Corp. (NASDAQ:UTHR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday. The brokerage presently has a $137.00 price objective on the biotechnology company’s stock. Zacks Investment Research’s price target indicates a potential upside of 12.29% from the stock’s current price.
According to Zacks, “United Therapeutics holds a strong position in the pulmonary arterial hypertension (PAH) market with four approved products targeting this indication. The company’s latest PAH offering, Orenitram, should continue to witness a pick-up in sales on the back of new patient starts, increasing patient referrals, and increasing uptake in community centers. However, PAH sales could be impacted by the warehousing effect with patients waiting to be treated with newer products like Orenitram and Actelion’s Uptravi. Meanwhile, we believe the company needs to use cash suitably to deal with generic competition for flagship product Remodulin that could materialize post Oct 2017 and should work on expanding its portfolio. Tyvaso and Orenitram are also facing patent challenges. Competition in the PAH market is also increasing.”
Other equities research analysts have also issued research reports about the company. Cowen and Company reiterated a “buy” rating and issued a $144.00 price target on shares of United Therapeutics Corp. in a research note on Friday, September 23rd. Jefferies Group reiterated a “hold” rating and issued a $120.00 price target on shares of United Therapeutics Corp. in a research note on Friday, July 29th. HC Wainwright reiterated a “hold” rating on shares of United Therapeutics Corp. in a research note on Friday, July 29th. Argus restated a “hold” rating on shares of United Therapeutics Corp. in a research report on Tuesday, August 23rd. Finally, JPMorgan Chase & Co. cut their price objective on United Therapeutics Corp. from $145.00 to $129.00 and set a “neutral” rating for the company in a research report on Friday, July 29th. Eight equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. United Therapeutics Corp. has an average rating of “Hold” and a consensus price target of $137.09.
United Therapeutics Corp. (NASDAQ:UTHR) traded down 3.873% during midday trading on Wednesday, reaching $117.285. The company had a trading volume of 366,571 shares. United Therapeutics Corp. has a 52 week low of $97.52 and a 52 week high of $164.04. The firm has a 50-day moving average price of $124.13 and a 200-day moving average price of $115.99. The company has a market capitalization of $5.10 billion, a price-to-earnings ratio of 5.671 and a beta of 1.46.
United Therapeutics Corp. (NASDAQ:UTHR) last issued its quarterly earnings results on Thursday, July 28th. The biotechnology company reported $4.55 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.22 by $1.33. United Therapeutics Corp. had a return on equity of 49.30% and a net margin of 64.26%. The business earned $412.60 million during the quarter, compared to analyst estimates of $395.15 million. During the same quarter in the prior year, the business posted $2.55 EPS. United Therapeutics Corp.’s revenue for the quarter was up 18.8% compared to the same quarter last year. Analysts expect that United Therapeutics Corp. will post $15.82 EPS for the current fiscal year.
In other news, CEO Martine A. Rothblatt sold 1,308 shares of United Therapeutics Corp. stock in a transaction that occurred on Thursday, June 30th. The shares were sold at an average price of $105.10, for a total transaction of $137,470.80. Following the completion of the sale, the chief executive officer now owns 1,548 shares of the company’s stock, valued at $162,694.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Martine A. Rothblatt sold 1,249 shares of United Therapeutics Corp. stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $125.78, for a total transaction of $157,099.22. Following the sale, the chief executive officer now directly owns 1,389 shares of the company’s stock, valued at approximately $174,708.42. The disclosure for this sale can be found here. 7.50% of the stock is currently owned by company insiders.
Several hedge funds have recently bought and sold shares of the stock. Daiwa Securities Group Inc. increased its stake in United Therapeutics Corp. by 16.7% in the second quarter. Daiwa Securities Group Inc. now owns 1,050 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 150 shares in the last quarter. Nordea Investment Management AB increased its stake in United Therapeutics Corp. by 18.7% in the second quarter. Nordea Investment Management AB now owns 1,208 shares of the biotechnology company’s stock valued at $128,000 after buying an additional 190 shares in the last quarter. Eqis Capital Management Inc. bought a new stake in United Therapeutics Corp. during the second quarter valued at $254,000. Acrospire Investment Management LLC bought a new stake in United Therapeutics Corp. during the first quarter valued at $267,000. Finally, Creative Planning increased its stake in United Therapeutics Corp. by 330.4% in the second quarter. Creative Planning now owns 2,410 shares of the biotechnology company’s stock valued at $255,000 after buying an additional 1,850 shares in the last quarter.
United Therapeutics Corp. Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for United Therapeutics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corp. and related companies with MarketBeat.com's FREE daily email newsletter.